Director

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Institution	Shares	Value	Change
Robeco Institutional Asset Management B.V	791,092	$171M	INCREASED
Artemis Investment Management	570,974	$123M	DECREASED
Swedbank AB	320,622	$69M	INCREASED
Aegon Asset Management UK	241,101	$52M	DECREASED
New York State Teachers Retirement System	108,004	$23M	DECREASED

Insider	Type	Shares	Date
Maria C Freire (Director)	AWARD	2,005	2026-06-09
Lloyd Minor (Director)	AWARD	1,505	2026-06-09
Menelas N Pangalos (Director)	AWARD	1,505	2026-06-09
Menelas N Pangalos (Director)	EXERCISE	2,370	2026-06-09
Monish D Patolawala (Director)	AWARD	1,505	2026-06-09

Member	Type	Amount	Date
Maria Elvira Salazar (Republican)	SALE	$15,001 - $50,000	2026-06-02
Gilbert Cisneros (Democrat)	PURCHASE	$1,001 - $15,000	2026-06-05
Maria Elvira Salazar (Republican)	PURCHASE	$1,001 - $15,000	2026-05-12

Biogen Inc. Common Stock (BIIB) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades